BenevolentAI Investor Conference Presentation Deck
High potential proprietary and partner pipeline
Chemistry &
Lead Opt
Programme
BEN-8744
BEN-28010
BEN-34712
Indication
Fibrosis
Ulcerative Colitis
Glioblastoma
Multiforme
Parkinson's Disease
ALS
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Target
PDE10
CHKI
RARaß
Novel Target
Novel Target
Multiple Targets
Multiple Targets
Oncology, neurology, immunology Multiple Targets
Phase 1 topline data readout: Q1 2024
IND-ready: Q4 2023 - completed
IND-ready: Q2 2024
Preclinical
AstraZeneca
MERCK
Regular re-evaluation of 10+ paused programmes and potential new pipeline entries
Discovery & Development Pipeline
End-to-End Drug Discovery
Phase 1
Phase 2
. Further AZ target selection potential across Heart
Failure and Systemic Lupus Erythematosus
• Initial delivery of 3 novel small molecule drug
candidates
Benevolent 17View entire presentation